These results highlight the functional integration of the two pathways in determining the global functional setting of the pancreatic cancer microenvironment and provide a proof of principle of the potential validity of a combined therapeutic treatment against BAG3 and SIRPα. The gene discussed is BAG3; the disease is familial pancreatic carcinoma.